Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LMO2 Double Nickase Plasmid (h): sc-402169-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LMO2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LMO2 Double Nickase Plasmid (h) and LMO2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LMO2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LMO2 Antibody (1A9-1): sc-65736
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LMO2 Double Nickase Plasmid (h) | sc-402169-NIC | 20 µg | $410.00 | |||
LMO2 Double Nickase Plasmid (h2) | sc-402169-NIC-2 | 20 µg | $410.00 |
LMO2 encodes a LIM domain–only transcriptional regulator that functions as a scaffold within multi-protein complexes controlling gene expression during hematopoiesis and vascular development. By bridging partners such as TAL1/SCL, GATA factors, and LDB1, LMO2 helps coordinate lineage specification, erythroid differentiation, and endothelial programs. Aberrant LMO2 expression or dysregulated complex assembly is linked to altered transcriptional circuitry in hematologic malignancies and other contexts where developmental transcription networks are reactivated. As a nodal regulator of cell fate, LMO2 is widely studied for its effects on proliferation, differentiation, and chromatin-associated transcriptional control.
LMO2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LMO2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LMO2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LMO2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LMO2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.